Better immune response from mixing Covaxin, Covishield, says ICMR study
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Monday
August 08, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
MONDAY, AUGUST 08, 2022
Better immune response from mixing Covaxin, Covishield, says ICMR study

Coronavirus chronicle

UNB
09 August, 2021, 03:15 pm
Last modified: 09 August, 2021, 04:29 pm

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Better immune response from mixing Covaxin, Covishield, says ICMR study

While Covishield is built on a viral vector vaccine platform and uses a weakened version of adenovirus, a common cold virus that causes infection in chimpanzees, Covaxin is built on an inactivated whole virus vaccine platform

UNB
09 August, 2021, 03:15 pm
Last modified: 09 August, 2021, 04:29 pm
The study found that immunisation with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity. Photo: UNB
The study found that immunisation with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity. Photo: UNB

A GROUP of 18 people, who had "inadvertently received Covishield as the first jab and Covaxin as the second", showed better immunogenicity — the ability to generate an immune response — than those who received two doses of the same vaccine, according to a new study by the Indian Council of Medical Research (ICMR), reports The Indian Express.

In May, 18 villagers in Siddarthnagar, Uttar Pradesh, had received Covaxin as the second dose, six weeks after they got Covishield. The study compared their reaction to 40 recipients of two doses of Covishield and 40 recipients of two doses of Covaxin.

"We compared the safety and immunogenicity profile of them (the group of 18) against that of individuals receiving either Covishield or Covaxin. Lower and similar adverse events following immunisation in all three groups underlined the safety of the combination vaccine-regime," said the study which is yet to be peer reviewed.

"Immunogenicity profile against Alpha, Beta and Delta variants in the heterologous group was superior; IgG antibody and neutralising antibody response of the participants was also significantly higher compared to that in the homologous groups," it said.

"Overall, this study demonstrates that immunisation with a heterologous combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine is safe and elicits better immunogenicity than two doses of homologous vaccination, using the same vaccines," it said.

While Covishield is built on a viral vector vaccine platform and uses a weakened version of adenovirus, a common cold virus that causes infection in chimpanzees, Covaxin is built on an inactivated whole virus vaccine platform.

The study is the first scientific evidence emerging from India on superior immunogenicity profile demonstrated in mixed-vaccine doses. However, the researchers have underlined that to conclusively prove these preliminary findings, "multi-centre" randomised control trials need to be carried out. They have also flagged the study's limitations: the sample size of 18 participants is small; follow-up period is only 60-70 days after first dose; baseline serological and immunological data of participants is not available.

According to the study, the findings have an "important implication" for the Covid-19 vaccination programme wherein "heterologous immunisation will pave the way for induction of improved and better protection against the variant strains of SARS-CoV-2".

"This is the first report of heterologous immunisation with an adenovirus vector based and an inactivated whole virion vaccine in humans demonstrating safety and significantly improved immunogenicity… Immunogenicity profile studied against the variants of concerns, Alpha, Beta and Delta variants, demonstrates significantly higher titers in the heterologous group," it said.

The researchers have said such mixed regimens will help to "overcome the challenges of shortfall of particular vaccines" and "remove hesitancy around vaccines in people's mind that could have genesis in programmatic 'errors' especially in settings where multiple Covid-19 vaccines are being used".

On safety, reactogenicity analysis showed that in the heterologous group, 11 per cent reported pain at the injection site; however, during the second dose, no such local adverse event was reported, it said.

The most commonly reported systemic adverse event was pyrexia (raised body temperature) and malaise (discomfort): 33.3 per cent reported this during the first dose, and 5.5 percent during the second dose. "No other systemic AEFI like, urticaria, nausea, vomiting, arthralgia or cough was reported," said the study.

Currently, the Indian drug regulator has granted permission to CMC Vellore to conduct Phase 4 clinical trials to assess the efficacy of a combination of Covishield and Covaxin doses as compared to the current protocol of using two doses of the same vaccine

Top News / World+Biz

COVAXIN / Covishield / ICMR

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • TBS file photo
    Now 99% Bangladesh products come under China’s duty-free offer
  • Photo: TBS
    Production loss feared as zone-wise industrial weekly closure mulled 
  • Representational image. File Photo: Minhaj Uddin/TBS
    LC settlement fell by $1.17b in July

MOST VIEWED

  • People line up for nucleic acid tests during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    China's Sanya holiday hotspot shuts duty-free malls, venues to curb Covid
  • FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea May 15, 2020, in this photo released by Kyodo. Mandatory credit Kyodo/via REUTERS
    North Korea marks end of first Covid wave, but risks persist
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    South Africa reports first death causally linked to Covid vaccine
  • 'Living with Covid': Where the pandemic could go next
    'Living with Covid': Where the pandemic could go next
  • A worker, wearing a protective suit following the coronavirus disease (COVID-19) outbreak, transports luggage on the tarmac of Wuhan Tianhe International Airport, on a hot summer day in Wuhan, Hubei province, China July 14, 2022. cnsphoto via REUTERS
    China's Wuhan locks down 1m residents amid new Covid cases
  • Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel
    Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Features

Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

20h | Mode
Infograph: TBS

Why a drastic fuel price hike is dangerous

1d | Panorama
A fuel price hike to fuel agony

A fuel price hike to fuel agony

1d | Panorama
Kamal Uddin Mazumder. Sketch: TBS

Rising foreign debt and balance of payments deficit: Does Bangladesh need to worry?

1d | Thoughts

More Videos from TBS

How Google Maps operates in Bangladesh

How Google Maps operates in Bangladesh

9h | Videos
Is BPC really in loss?

Is BPC really in loss?

11h | Videos
Reasons behind Putin-Erdogan's meeting in Sochi

Reasons behind Putin-Erdogan's meeting in Sochi

15h | Videos
Dr Jamaluddin Ahmed talks about recent fuel price hike

Dr Jamaluddin Ahmed talks about recent fuel price hike

15h | Videos

Most Read

1
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

2
Housing projects sprouting up by Dhaka-Mawa expressway
Real Estate

Housing projects sprouting up by Dhaka-Mawa expressway

3
July remittance hits two-year high
Economy

July remittance hits two-year high

4
Infographic: TBS
Banking

Dollar rate will be left to market after two months: Governor

5
Bangladesh to resume talks for Ukrainian wheat import
Economy

Bangladesh to resume talks for Ukrainian wheat import

6
A liquefied natural gas (LNG) tanker is tugged towards a thermal power station in Futtsu, east of Tokyo, Japan November 13, 2017. REUTERS/Issei Kato/File Photo
Energy

Summit proposes long-term LNG supply to Petrobangla

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net